Insmed Incorporated
General ticker "INSM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $18.5B (TTM average)
Insmed Incorporated follows the US Stock Market performance with the rate: 53.7%.
Estimated limits based on current volatility of 1.6%: low 203.58$, high 210.08$
Factors to consider:
- Total employees count: 1271 as of 2024
- US accounted for 70.1% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Net losses and future profitability, Cybersecurity threats, Labor/talent shortage/retention, Geopolitical risks, Economic downturns and volatility
- Current price 131.8% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [36.58$, 88.47$]
- 2025-12-31 to 2026-12-31 estimated range: [21.91$, 56.93$]
Financial Metrics affecting the INSM estimates:
- Negative: with PPE of -12.5 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -5.96 <= 0.33
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of 14.09 <= 18.93
- Positive: Industry inventory ratio change (median), % of -0.48 <= -0.15
- Negative: negative Industry operating cash flow (median)
- Positive: -14.38 < Investing cash flow per share per price, % of -5.09
Short-term INSM quotes
Long-term INSM plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $245.36MM | $305.21MM | $363.71MM |
| Operating Expenses | $702.68MM | $1,014.83MM | $1,241.96MM |
| Operating Income | $-457.32MM | $-709.63MM | $-878.25MM |
| Non-Operating Income | $-22.83MM | $-37.39MM | $-31.81MM |
| Interest Expense | $26.45MM | $81.69MM | $84.91MM |
| R&D Expense | $397.52MM | $571.01MM | $598.37MM |
| Income(Loss) | $-480.15MM | $-747.01MM | $-910.07MM |
| Taxes | $1.38MM | $2.56MM | $3.71MM |
| Profit(Loss)* | $-481.53MM | $-749.57MM | $-913.77MM |
| Stockholders Equity | $87.95MM | $-331.92MM | $285.38MM |
| Inventory | $69.92MM | $83.25MM | $98.58MM |
| Assets | $1,656.43MM | $1,329.84MM | $2,025.23MM |
| Operating Cash Flow | $-400.44MM | $-536.25MM | $-683.88MM |
| Capital expenditure | $9.88MM | $13.29MM | $21.92MM |
| Investing Cash Flow | $-34.58MM | $-223.60MM | $-583.17MM |
| Financing Cash Flow | $793.27MM | $168.44MM | $1,341.02MM |
| Earnings Per Share** | $-3.91 | $-5.34 | $-5.57 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.